Patent · US Expired

Treatment of hemolytic anemia with danazol

US4837212A · kind A · utility

8Cited by
1References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 1, 1986
Grant dateJun 6, 1989
Priority date
Expiry dateDec 1, 2006

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K31/58
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Danazol, a known androgen, is used to (1) correct immune abnormalities associated with hemotologic disorders or (2) treating immune disorders associated with depressed T helper cells, in the invention disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.